美股異動 | BioNTech(BNTX.US)盤前漲2.25% 消息稱FDA將很快授權其新冠加強針用於5-11歲兒童
格隆匯5月17日丨BioNTech(BNTX.US)盤前漲2.25%,報154.6美元。據紐約時報援引消息人士稱,美國食品藥物管理局(FDA)預計將在週二批准為5-11歲兒童接種輝瑞-BioNTech新冠疫苗加強針。上述公司4月向FDA提交了授權申請。目前還不清楚該年齡組對加強針的需求有多大。根據美國疾病控制和預防中心的數據,目前美國只有28.8%的5-11歲的兒童完全接種新冠疫苗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.